Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.40+0.15 (+1.62%)
Close on Nov 17, 2026Market cap $558.21MP/E 10.1Yield –
Zevra Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Zevra Therapeutics's enterprise value was $481.63M on Nov 11, 2026, against $335.72M a year earlier. Over the last 5 years it ranged from $44.13M to $647.09M, with a median of $217.31M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $481.63M | +31.8% |
| 2025 | Dec 31, 2025 | $365.51M | -11.6% |
| 2024 | Dec 31, 2024 | $413.44M | +159.5% |
| 2023 | Dec 29, 2023 | $159.32M | +93.2% |
| 2022 | Dec 30, 2022 | $82.47M | -53.2% |
| 2021 | Dec 31, 2021 | $176.11M | +280.6% |
| 2020 | Dec 31, 2020 | $46.27M | +702.5% |
| 2019 | Dec 31, 2019 | $5.77M | -62.9% |
| 2018 | Dec 31, 2018 | $15.53M | +19.2% |
| 2017 | Dec 29, 2017 | $13.02M | – |
| 2016 | Dec 30, 2016 | -$21.42M | -109.6% |
| 2015 | Dec 31, 2015 | $223.83M | – |
See a number that looks wrong?